Alliance Imaging to repurchase preferred stock:
This article was originally published in Clinica
Alliance Imaging has signed an agreement with shareholders to repurchase certain of its securities by the end of the year. Alliance will pay $16.8 million cash plus accrued dividends and interest, and will fund the repurchase of the securities through the sale of a new issue of preferred stock.
You may also be interested in...
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.